PEG-modified uricase
US6913915B2 · kind B2 · utility
68Cited by
16References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 2, 2001 |
| Grant date | Jul 5, 2005 |
| Priority date | — |
| Expiry date | Aug 2, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to uricase modified with polyethylene glycol and to methods of treating different illnesses characterized by increased circulating uric acid levels, including but not limited to, hyperuricemia and tumor lysis syndrome.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.